PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years

Patent Foramen Ovale Clinical Trial

— CLOSE-2  

Official title:

Transcatheter Patent Foramen Ovale (PFO) Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Between 60 and 80 Years Old : a Randomised Controlled Trial.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05387954
• Other study ID #: APHP211041
• Secondary ID: 2021-A03197-34PH
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: June 1, 2022
• Est. completion date: June 1, 2030

Study information

• Verified date: May 2022
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Aurélie Guimfack
• Phone: +331 44 84 17 98
• Email: aurelie.guimfack[@]aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess whether PFO closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy to prevent stroke recurrence in patients aged 60 to 80 years with a PFO with large shunt (> 20 microbubbles) or a PFO associated with an ASA (> 10 mm), and an otherwise unexplained ischemic stroke.

Description:

The CLOSE trial (NCT00562289, NEJM 2017) has unambiguously demonstrated the superiority of patent foramen ovale (PFO) closure over antiplatelet therapy alone in patients aged up to 60 years with a PFO associated with an atrial septal aneurysm (ASA) or a large right-to-left shunt (so-called "high-risk PFO"), and an otherwise unexplained ischemic stroke. Oral anticoagulant therapy is also a logical approach assuming that PFO-related strokes are due to paradoxical embolism which implies a venous source of embolism, or to direct embolization of a thrombus formed at the atrial level. The CLOSE trial also suggested that oral anticoagulants might reduce stroke recurrence compared to aspirin. There is accumulating evidence that presence of a PFO is significantly associated with cryptogenic stroke in patients over 60 years. Cryptogenic ischemic strokes represent about one third of all ischemic strokes in patients older than 60 years. However, the optimal therapeutic strategy in patients older than 60 years with a PFO and an otherwise unexplained ischemic stroke is unknown, because these patients were excluded from randomized trials. The hypothesis tested in this trial is that transcatheter PFO closure plus long-term antiplatelet therapy is superior to antiplatelet therapy alone and that oral anticoagulant therapy is superior to antiplatelet therapy to prevent recurrent stroke in patients aged 60 to 80 years who have a high-risk PFO and a recent otherwise unexplained ischemic stroke.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 792
• Est. completion date: June 1, 2030
• Est. primary completion date: June 1, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 80 Years

Eligibility

Inclusion Criteria:

• Man or woman aged 60 to 80 years.
• Recent (= 6 months) ischemic stroke confirmed by cerebral imaging regardless of symptom duration.
• Absence of a more probable cause of stroke than PFO after a standardized etiological work-up (see addenda). Presence of a PFO with at least 1 of the 2 following

characteristics:

• PFO with large shunt (> 20 microbubbles appearing inthe left atrium within 3 cardiac cycles after opacification of the right atrium) detected spontaneously or during provocative maneuvers,
• PFO with ASA on transesophageal echocardiography (TOE): base of aneurysm >= 15mm and excursion >10 mm.
• Affiliation to a French Health Insurance system. Informed consent.

Exclusion Criteria:

• Life expectancy < 4 years.
• Contraindication to both experimental treatments (PFO closure, oral anticoagulant therapy) or to the reference treatment (antiplatelet therapy) (see paragraph 19.5). Indication to long-term anticoagulant therapy.
• mRS >= 3.
• Presence of other medical conditions that would lead to inability to complete the study or interfere with the assessment of outcomes.
• Previous surgical or transcatheter treatment of PFO or ASA. Expected impossible follow-up or poor compliance.
• Patient unable to understand the informed consent form. Patient under tutorship, curatorship, or legal protection.

Related Conditions & MeSH terms

• Cryptogenic Ischemic Stroke
• Foramen Ovale, Patent
• Ischemic Stroke
• Patent Foramen Ovale
• Stroke

Intervention

Procedure:
• Transcatheter PFO closure
PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel until the end of the study.

Drug:
• Oral Anticoagulant, Direct-Acting
Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
• Antiplatelet therapy
Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel

Locations

Country	Name	City	State
France	CHU Amiens	Amiens
France	CH Arras	Arras
France	CHU Jean Minjoz	Besançon
France	CHU Bordeaux - GH Pellegrin	Bordeaux
France	CHRU La Cavale Blanche	Brest
France	HCL-Groupement Hospitalier Lyon Est	Bron
France	CHU Côte de Nacre	Caen
France	Hôpital Henri Mondor	Créteil
France	CHU Dijon-Hôpital François Mitterrand	Dijon
France	CH Grenoble-Site Nord	Grenoble
France	CH Versailles-Hôpital Mignot	Le Chesnay
France	CHU Bicêtre	Le Kremlin-Bicetre
France	CHRU Lille-Hôpital Salengro	Lille
France	Hôpital de la Timone	Marseille
France	Hôpital Gui de Chauliac	Montpellier
France	CHRU Nancy-Hôpital central	Nancy
France	CHU Carémeau	Nîmes
France	APHP Hôpital Bichat	Paris
France	APHP Hôpital Lariboisière	Paris
France	Fondation Adolphe de Rothschild	Paris
France	GHU Paris Psychiatrie et Neurosciences	Paris
France	Groupe Hospitalier Paris Saint-Joseph	Paris
France	Hôpital Pitié Salpêtrière	Paris
France	CH Perpignan	Perpignan
France	CHU La Milétrie	Poitiers
France	CHU Rouen-Hôpital Charles-Nicolle	Rouen
France	CH Yves Le Foll	Saint Brieuc
France	CHU Nantes-Hôpital Nord Laennec	Saint Herblain
France	CHU Saint-Etienne-Hôpital Nord	Saint-Priest en Jarez
France	Hôpital Hautepierre	Strasbourg
France	CHU Toulouse-Hôpital Pierre Paul Riquet	Toulouse

Sponsors (6)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Abbott, Centre Hospitalier St Anne, Gore, Ministry of Health, France, Occlutech International AB

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to recurrent stroke (ischemic or hemorrhagic fatal or non-fatal)	Stroke: sudden onset of focal neurological symptoms related to a disturbance of the cerebral circulation.; Ischemic stroke : at least one of the following criteria: Sudden onset of focal neurological symptoms with the presence of cerebral infarction in the appropriate territory on brain imaging (CT or MRI), regardless of the duration of symptoms (less than or more than 24 hours).; Sudden onset of focal neurological symptoms lasting more than 24 hours, with no apparent cause other than cerebral ischemia.; Intracerebral hemorrhage: sudden onset of focal neurological symptoms with the presence of cerebral hemorrhage in the appropriate territory on brain imaging (CT or MRI), regardless of the duration of symptoms (less than or more than 24 hours) and regardless of the cause of the hemorrhage (spontaneous or secondary to trauma, tumour or another cause).; Unknown type of stroke : the type of stroke cannot be determined with certainty and the symptoms last more than 24 hours.	From date of randomization until the date of first recurrent stroke, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Secondary	Time to disabling stroke	mRS score greater than or equal to 3, with an increase of at least 2 points compared to the last mRS score before the stroke.	From date of randomization until the date of first recurrent disabling stroke, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Secondary	Time to ischemic stroke	At least one of the following criteria: Sudden onset of focal neurological symptoms with the presence of cerebral infarction in the appropriate territory on brain imaging (CT or MRI), regardless of the duration of symptoms (less than or more than 24 hours).; Sudden onset of focal neurological symptoms lasting more than 24 hours, with no apparent cause other than cerebral ischemia.	From date of randomization until the date of first recurrent ischemic stroke, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Secondary	Time to ischemic stroke or systemic embolism	Clinical features related to embolism usually affecting a limb, mesenteric, splenic, or renal artery. The diagnosis of embolism must be confirmed by appropriate investigations.	From date of randomization until the date of first recurrent ischemic stroke or systemic embolism, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Secondary	Time to transient ischemic attack,	Sudden onset of neurological symptoms, presumed to be ischemic, resolving in less than 24 hours, clearly attributable to focal involvement of the central nervous system (or of the eye) with no signs of a corresponding recent cerebral infarction on brain imaging. The diagnosis of TIA will be confirmed by a neurologist, considering clinical data and brain imaging (MRI with diffusion sequence is recommended).	From date of randomization until the date of first transient ischemic attack, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Secondary	Time to vascular death	death related to a cardiac or vascular cause.; death due to hemorrhage.; death due to pulmonary embolism.; sudden death: death occurring in less than 24 hours, unexpectedly in a subject in apparent good health and whose condition was stable or was improving.; death with no documented non-vascular cause.; fatal stroke: death occurring within 30 days of a stroke (ischemic or hemorrhagic).	From date of randomization until the date of vascular death, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Secondary	Time to all-cause mortality	Vascular (see definition) or nonvascular death: death due to a documented non-vascular cause (infection, cancer, accident, suicide, etc.).	From date of randomization until the date of death, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Secondary	Quality of life score	Measured by using the European Quality Of Life (EQ-5D) auto-questionnaire. The digits for the five dimensions are combined into a 5-digit number that describes the patient's health state. The visual analogue scale (VAS) records the patient's self-rated health on a vertical axis from 0 (worst health) to 100 (best health)	Every 6 months after randomization or up to 4 years (for the last patient included) to up to 8 years (for the first patient included)]
Secondary	Time to fatal, life-threatening or major hemorrhage, including intracerebral and Intracranial hemorrhage	Life-threatening; Fatal hemorrhage.; Drop in hemoglobin by = 5 g/dL (or drop in hematocrit by 15% or more in absolute value); Symptomatic intracranial hemorrhage (confirmed by appropriate investigations, classified as cerebral hemorrhage, subarachnoid hemorrhage and subdural hematoma).; Transfusion = 4 units of packed cells (or equivalent of whole blood)*.; Major; Transfusion = 3 units of packed cells (or equivalent of whole blood)*.; Requiring hospitalization (or prolonging hospitalization).; Requiring surgical treatment.; Intraocular hemorrhage with significant loss of vision.; Other hemorrhage responsible for significant disability according to the investigator.	From date of randomization until the date of first fatal,life-threatening or major hemorrhage,including intracerebral and Intracranial hemorrhage,assessed from up to 4 years(for the last patient included) to up to 8 years(for the first patient included)
Secondary	Proportion of success of device implantation, of the procedure and of PFO closure,	Success of device implantation: deployment of the device in the appropriate place and removal of the placement system.; Success of the procedure: successful implantation with no complications before the patient's discharge.; Success of PFO closure: success of the procedure with no residual shunt or minimal residual shunt on echocardiography performed 6 months after the procedure.	6 months after PFO closure
Secondary	Time to ischemic stroke recurrence according to the presence of a residual shunt	From control echocardiography after PFO closure to the end of the patient's follow-up	From date of PFO closure until the date of first ischemic stroke recurrence, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included), according to the presence of residual shunt]
Secondary	Time to new-onset atrial fibrillation	Atrial fibrillation lasting at least 30 seconds	From date of randomization until the date of new-onset atrial fibrillation, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)]
Secondary	Proportion of fatal, life-threatening or major procedure- or device-related complications	Life-threatening; Cardiac perforation with tamponade requiring emergency drainage.; Cerebral air embolism responsible for acute neurological disorders; Embolization of the device.; Life-threatening hematoma at the puncture site or retroperitoneal.; Complications of general anesthesia or TOE requiring intensive care and/or surgical operation.; Major; Hemorrhage at the puncture site or retroperitoneal requiring transfusion or surgery.; Arteriovenous fistula, pseudoaneurysm requiring surgery.; Peripheral nerve lesion with disabling neurological deficit persisting > 1 month.; Cardiac arrhythmias (particularly AF) during catheterization or post-procedure requiring treatment >= 1 month.; Infective endocarditis.; Asymptomatic late thrombosis of the device.; Any device-related complication requiring surgery.; Any other complication related to the transcatheter treatment or anesthesia, considered to be major by the investigator.	Within 4 weeks following the procedure (PFO closure)
Secondary	Costs	Costs will be estimated from the viewpoint of the healthcare system (hospital admission, transportation, study interventions, emergency room visit without admission,consultations,imaging)	Within 48 months after randomization
Secondary	Incremental cost-utility ratio at 4 years (ICUR)	The incremental cost-utility ratio (ICUR) will be calculated as difference in costs (between groups)/difference in QALYs (Quality-Adjusted Life Year) between groups.; The QALYs will be constructed with the EuroQoL-5D (EQ-5D) questionnaire and value sets	Within 48 months after randomization